A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

被引：0
|
作者：
Montesinos, Pau
Al-Ali, Haifa
Alonso-Dominguez, Juan M.
Jentzsch, Madlen
Jongen-Lavrencic, Mojca
Martelli, Maria Paola
Rollig, Christoph
Sica, Simona
Iadevaia, Riham
Yablonski, Kaitlin
Wang, Tianli
Mahmood, Zafar
Koenen, Giedre
Schmidt, Hank
Yang, Jingsong
Yee, Karen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT124
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [2] Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Winer, Eric S.
    Garcia, Jacqueline S.
    Stone, Richard M.
    Wadleigh, Martha
    Luskin, Marlise R.
    Stahl, Maximilian
    Chen, Evan C.
    Leonard, Rebecca
    Noyes, Alexis
    Galinsky, Ilene
    Deshpande, Rashmi
    Borderies, Pascal
    O'Neill, Vincent
    DeAngelo, Daniel J.
    BLOOD, 2023, 142
  • [3] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [4] Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
    Lee, Je-Hwan
    Faderl, Stefan
    Pagel, John M.
    Jung, Chul Won
    Yoon, Sung-Soo
    Pardanani, Animesh D.
    Becker, Pamela S.
    Lee, Howard
    Choi, Jeongeun
    Lee, Kyoungjune
    Kim, Minkyoung
    Cortes, Jorge E.
    BLOOD ADVANCES, 2020, 4 (09) : 2032 - 2043
  • [5] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    N Daver
    H Kantarjian
    F Ravandi
    E Estey
    X Wang
    G Garcia-Manero
    E Jabbour
    M Konopleva
    S O'Brien
    S Verstovsek
    T Kadia
    C Dinardo
    S Pierce
    X Huang
    N Pemmaraju
    M Diaz-Pines-Mateo
    J Cortes
    G Borthakur
    Leukemia, 2016, 30 : 268 - 273
  • [6] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Daver, N.
    Kantarjian, H.
    Ravandi, F.
    Estey, E.
    Wang, X.
    Garcia-Manero, G.
    Jabbour, E.
    Konopleva, M.
    O'Brien, S.
    Verstovsek, S.
    Kadia, T.
    Dinardo, C.
    Pierce, S.
    Huang, X.
    Pemmaraju, N.
    Diaz-Pines-Mateo, M.
    Cortes, J.
    Borthakur, G.
    LEUKEMIA, 2016, 30 (02) : 268 - 273
  • [7] A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    Chen, Yiming
    Kantarjian, Hagop
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Rey, Kristy
    Cortes, Jorge
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 341 - 344
  • [8] Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome
    Benajiba, Lina
    Carraway, Hetty E.
    Hamad, Nada
    Stein, Eytan M.
    Yannakou, Costas K.
    Burroughs, Amy
    Harris, Scott
    Lane, Hayley
    Nguyen, Dorothy D.
    Stuart, Monic
    Vargas, Jesse
    Puissant, Alexandre
    Stegmaier, Kimberly
    DiNardo, Courtney D.
    BLOOD, 2020, 136
  • [9] Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Cortes, Jorge E.
    Faderl, Stefan
    Pagel, John
    Jung, Chul Won
    Yoon, Sung-Soo
    Koh, Youngil
    Pardanani, Animesh Dev
    Hauptschein, Robert S.
    Lee, Kyoung-June
    Lee, Je-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Assi, Rita
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Daver, Naval
    Estrov, Zeev
    Uehara, Taisuke
    Owa, Takashi
    Cortes, Jorge E.
    Borthakur, Gautam
    CANCER, 2018, 124 (13) : 2758 - 2765
12345